A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Kopińska et al.|Blood|2025Cited by 1
Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell TransplantationAnna Czyż, Agnieszka Wierzbowska, Małgorzata Sobczyk‐Kruszelnicka et al.|Blood|2022Cited by 0
A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline ResultsAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2024Cited by 0
Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 studyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2025Cited by 0